News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Ascletis, Inc. Named for Financing Deal of the Year



11/30/2011 12:32:13 PM

November 30, 2011 -- China biopharma Ascletis was nominated as the initial contender for InVivo Blog's contest that will choose the best Exit/Financing Deal of the Year from around the globe. Ascletis was chosen because its $100 million Series A funding was one of the highest ever for a biotech. Most Series A rounds are in the $5-$10 million range, and only 10% of this year’s initial fundings surpassed $40 million, making Ascletis's accomplishment a standout performance. More details....

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES